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Abstract
Latent inhibition (LI) manifests as poorer conditioning to a stimulus that has previously been experienced
without consequence. There is good evidence of dopaminergic modulation of LI, as the eﬀect is reliably
disrupted by the indirect dopamine (DA) agonist amphetamine. The disruptive eﬀects of amphetamine on
LI are reversed by both typical and atypical antipsychotics, which on their own are able to facilitate LI.
However, the contribution of diﬀerent DA receptors to these eﬀects is poorly understood. Amphetamine
eﬀects on another stimulus selection procedure, overshadowing, have been suggested to be D1-mediated.
Thus, in the current experiments, we systematically investigated the role of D1 receptors in LI. First, we
tested the ability of the full D1 agonist SKF 81297 to abolish LI and compared the eﬀects of this drug on LI
and overshadowing. Subsequently, we examined whether the D1 antagonist SCH 23390 can lead to the
emergence of LI under conditions that do not produce the eﬀect in normal animals (weak pre-exposure).
Finally, we tested the ability of SCH23390 to block amphetamine-induced disruption of LI. We found little
evidence that direct stimulation of D1 receptors abolishes LI (although there was some attenuation of LI
at 0.4 mg/kg SKF 81297). Similarly, SCH23390 failed to enhance LI. However, SCH23390 did block
amphetamine-induced disruption of LI. These data indicate that, while LI may be unaﬀected by selective
manipulation of activity at D1 receptors, the eﬀects of amphetamine on LI are to some extent dependent on
actions at D1 receptors.
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Introduction
Latent inhibition (LI) manifests as poorer conditioning
to a stimulus that has previously been experienced
(‘pre-exposed’) without consequence (Lubow &
Moore, 1959). There is compelling evidence that the
normal eﬀect of pre-exposure at conditioning is
modulated by dopaminergic mechanisms (Weiner,
1990, 2003). First, LI is abolished by the indirect do-
pamine (DA) agonist amphetamine and this eﬀect
is antagonized by both typical and atypical anti-
psychotics (e.g. Crider et al. 1982; Solomon et al. 1981;
Weiner et al. 1984). Moreover, under experimental
conditions that do not produce LI in controls, anti-
psychotics given on their own are able to facilitate LI
(Feldon &Weiner, 1991 ; Shadach et al. 2000; Weiner &
Feldon, 1987). Further studies have shown that both
the disruption and enhancement of LI by dopaminer-
gic drugs is modulated by the mesolimbic DA system.
For example, infusions of amphetamine into the
nucleus accumbens disrupt LI whereas haloperidol
microinjected into the shell enhances LI (Joseph et al.
2000; Nelson et al. 2011a, b). Disruption to LI manifests
as increased conditioning to a stimulus that would
normally be treated as irrelevant. As aberrant
processing of stimulus salience has been posited to
contribute to the cognitive inﬂexibility seen in schizo-
phrenia (Bleuler, 1911 ; Cassaday & Moran, 2010 ;
Gray et al. 1991, 1999 ; Kapur, 2003, 2004), LI has
gained widespread acceptance as a preclinical model
for schizophrenic attention disorder.
LI is just one of a series of procedures employed to
examine the neural substrates of stimulus selection.
For example, overshadowing procedures use the
relative intensity of competing cues to manipulate
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associability. Normally a more intense stimulus
acquires associative strength at the expense of a
relatively less intense stimulus (Pavlov, 1927). Over-
shadowing has similarly been shown to be dis-
rupted by acute treatment with amphetamine
(O’Tuathaigh & Moran, 2002, 2004 ; O’Tuathaigh et al.
2003).
Although both LI and overshadowing can be
disrupted by amphetamine, there is evidence to sug-
gest that the pharmacological proﬁle of these eﬀects
may diﬀer. For example, the disruptive eﬀects of
amphetamine on LI are blocked by typical anti-
psychotics, such as haloperidol, as well as by atypical
antipsychotics (e.g. Gosselin et al. 1996; Warburton
et al. 1994; Weiner et al. 1996). It has therefore been
suggested that the eﬀects of these drugs on LI are
meditated by their actions at D2 receptors (e.g. Weiner,
2003). On the other hand, the disruptive eﬀects of
amphetamine on overshadowing are not blocked
by the D2 antagonists haloperidol, raclopride or
sulpriride but are reversed by the D1 antagonist
SCH23390 (O’Tuathaigh & Moran, 2002, 2004). These
data indicate that amphetamine eﬀects on LI and
overshadowing are diﬀerentially sensitive to antag-
onism of D1 and D2 receptors. Consistent with this
dissociable pharmacological proﬁle, the partial D1
agonist SKF 38393 is able to disrupt overshadowing
but not LI (Feldon et al. 1991; Loskutova et al. 2010;
O’Tuathaigh & Moran, 2002 ; Zelikowsky & Fanselow,
2010).
However, recent evidence has suggested that D1
receptors may, under certain circumstances, be in-
volved in the mediation of LI (Bay-Richter et al. 2009).
Moreover, to date, the eﬀects of a full D1 agonist have
not been tested on LI and although there is evidence
that D1 antagonists do not potentiate LI on their own
(Trimble et al. 2002), the ability of a D1 antagonist to
reverse amphetamine-induced disruption of LI has
not been examined. Thus, in the current experiments
we compared the eﬀects of the full D1 agonist SK 81297
(at two doses) on both LI and overshadowing. Where
disruptive eﬀects of the agonist were demonstrated,
expt 2 followed up on these results, examining the
eﬀects the eﬀects of a D1 antagonist (SCH23390),
now using experimental parameters suitable to test
for behavioural enhancement (reduced number of
stimulus pre-exposures to produce a weaker LI eﬀect).
Finally, using the same parameters as expt 1 [30
conditioned stimulus (CS) pre-exposures, which yield
robust LI in normal animals and are suitable to
show amphetamine-induced abolition], we examined
whether SCH23390 would block the disruptive eﬀects
of amphetamine on LI.
Experimental procedures
Subjects
Subjects were adult male Wistar rats (Charles River,
UK), caged in pairs on a 12-h light/dark cycle (lights
on 07:00 hours) with food and water ad libitum. Rats
were handled for approximately 10 min/d for 1 wk.
In expts 1a, 1b and 2, there were 72 animals run in a
single replication. Expt 3 was run in two replications
with 48 rats per replication.
All procedures were carried out in accordance with
the UK Animals Scientiﬁc Procedures Act 1986, Project
Licence number : PPL 40/3163. The UK Act ensures
full compliance with the ‘Principles of laboratory
animal care’ (NIH publication No. 86-23, revised
1985).
Apparatus
Six identical fully automated conditioning chambers,
housed within sound-attenuating cases containing
ventilation fans (Cambridge Cognition, UK), were
used. Each of the inner conditioning chambers con-
sisted of a plain steel box (25 cmr25 cmr22 cm high)
with a Plexiglas door (27 cmr21 cm high) at the front.
The ﬂoor was a shock grid with steel bars 1 cm apart
and 1 cm above the lip of a 7 cm deep sawdust tray.
A waterspout was mounted on one wall. The spout
was 5 cm above the ﬂoor and connected to a lick-
ometer supplied by a pump. Licks were registered by
a break in the photo beamwithin the spout, which also
triggered water delivery of 0.05 ml per lick. The
waterspout was illuminated when water was avail-
able. A loudspeaker for the presentation of auditory
stimuli was set in the roof. In all but expt 2b, a 5 s
ﬂashing light, provided by the three wall-mounted
stimulus lights and the house light ﬂashing both on
(0.5 s) and oﬀ (0.5 s) served as the CS. In the over-
shadowing condition (expt 1 only), the 5 s light CS was
presented in compound with a 5 s mixed frequency
noise set at 85 dB (including background noise from
the fans). In expt 2b, the 5 s mixed frequency noise
(again set at 85 dB including background noise from
the fans) was used as the CS. Footshock of 1 s duration
and 1 mA intensity provided the unconditioned
stimulus (UCS). This was delivered through the grid
ﬂoor by a constant current shock generator (pulsed
voltage : output square wave 10 ms on, 80 ms oﬀ,
370 V peak under no load conditions ; MISAC Systems,
UK). Stimulus control and data collection was by an
Acorn Archimedes RISC computer programmed in
Basic with additional interfacing using an Arachnid
extension (Cambridge Cognition).
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Drugs
SKF 81297 (Tocris Bioscience, UK) at a dose of
0.8 mg/kg (expt 1a) and 0.4 mg/kg (expt 1b) was
administered (s.c.) 15 min prior to the pre-exposure
and conditioning stages of the experiment.
In expt 2, SCH23390 (Tocris Bioscience) was ad-
ministered at doses of 0.025 mg/kg or 0.05 mg/kg s.c.
15 min before both the pre-exposure and the con-
ditioning stages.
In expt 3, D-amphetamine (Amph; Sigma, UK) was
administered at a dose of 1 mg/kg s.c. 15 min before
both pre-exposure and conditioning. SCH23390
(Tocris Bioscience) at a dose of 0.02 mg/kg was
given 15 min before pre-exposure and conditioning.
Animals in the Amph+SCH23390 group received
an injection of Amph (1 mg/kg s.c.) immediately fol-
lowed by an injection of SCH23390 (0.02 mg/kg s.c.)
15 min before each stage of the LI procedure. The
SCH23390, Amph and saline controls animals each
received an additional saline injection so that all
animals in expt 3 received two injections.
In each experiment, drugs were dissolved in
physiological saline to an injection volume of 1 ml/kg.
All doses were calculated as the salt. Controls received
an equivalent volume of saline. Reshape and test
sessions were all conducted drug-free.
The 1 mg/kg dose of amphetamine is well-
established as a dose that disrupts LI (e.g. Nelson
et al. 2011a). SCH23390 doses in the range of
0.01–0.05 mg/kg have previously been shown to
antagonize amphetamine abolition of overshadowing
as well as block the disruptive eﬀects of nicotine on LI
(O’Tuathaigh & Moran, 2002 ; Young et al. 2005). The
dose of SCH23390 was reduced to 0.02 mg/kg in expt
3, based on the results of expt 2, and to match that
demonstrated to reverse the eﬀects of nicotine on LI
measured in the same fear conditioning procedure
(Young et al. 2005). The SKF 81297 doses were chosen
on the basis of their eﬀects in an operant conditioning
paradigm (Cheung et al. 2007).
Procedure
Water deprivation was introduced 1 d prior to shap-
ing. Thereafter, the animals received 1 h and 15 min
of ad libitum access to water in their home cage
in addition to water in the experimental chambers.
The stages of the conditioned emotional response
procedure used in expts 1–3 were as follows.
Pre-training
Rats were shaped for 1 d until all drank from the
waterspout and were individually assigned to a
conditioning box for the duration of the exper-
iment.
There then followed 5 d pre-training, in which rats
drank in the experimental chamber for 15 min each
day (timed from ﬁrst lick). The drinking spout was
illuminated throughout, but no other stimuli were
presented in this phase. Latency to ﬁrst lick was
measured as an indicator of habituation to the exper-
imental context. Total number of licks was also re-
corded each day to assess any pre-existing diﬀerences
in drinking (prior to conditioning).
Pre-exposure
Animals were placed in the chambers where the pre-
exposed (PE group) animals received 30r5 s light CS
presentations (expts 1 and 3) and 10r5 s light CS
presentations (expt 2a), with an average inter-stimulus
interval of 60 s. In expt 2b, the PE group were given
10r5 s noise CS presentations. The non-pre-exposed
(NPE) control animals and overshadowed groups
(expt 1 only) were conﬁned to the chambers for an
identical period of time (30 or 10 min) without re-
ceiving any CS presentations. Water was not available
within the chamber and the waterspout was not
illuminated during the pre-exposure session.
Conditioning
Conditioning was conducted on the day following
pre-exposure. No water was available within the
chamber and the waterspout was not illuminated.
There were two conditioning trials, in which the UCS
footshock was delivered following termination of the
CS. The ﬁrst pairing of CS and UCS was presented
after 5 min had elapsed and the second pairing was
5 min after the ﬁrst, followed by a further 5 min left in
the apparatus. In the absence of drinking, there were
no behavioural measures to record.
Reshaping
On the day following conditioning, animals were
reshaped following the same procedure as in pre-
training sessions. This was in order to re-establish
drinking after conditioning. Reshaping also provided
measures of conditioning to the box context (latency to
ﬁrst lick).
Test
On the day following reshape, the animals were
placed in the conditioning chambers and underwent
an extinction test to the light (or noise in expt 2b) CS.
Water was available throughout the test and the
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waterspout was illuminated. Once the animals had
made 50 licks, the CS was presented for 15 min.
The latency to make 50 licks in the absence of the CS
(‘A’ period) provided a measure of any individual
variation in baseline lick responding. This was com-
pared with the time taken to complete 50 licks fol-
lowing CS onset (‘B’ period) in a suppression ratio
(A/(A+B)) to assess the level of conditioning to the
CS, adjusted for any individual variation in drink rate.
Assessment of locomotor activity (expt 4)
In order to conﬁrm whether SCH23390 is able to block
the development of amphetamine sensitization, rats
that had previously been treated with either Amph or
Amph+SCH23390 were given an amphetamine chal-
lenge and underwent an assessment of locomotor ac-
tivity. On the day following the CS test, rats received a
0.5 mg/kg amphetamine challenge (s.c.) 10 min before
being placed in a novel arena, where locomotor ac-
tivity was monitored for 30 min. The arena consisted
of a Perspex box (39r23.5r24.5 cm) with an ex-
changeable ﬂoor and metal grid lid. This was ﬁtted
with two layers of parallel infrared photocell beams,
which, when broken, registered activity, recorded by a
computer.
Design and analysis
Expts 1a and 1b were run in a 3r2 factorial design
with between subject factors of conditioning group
(control, PE and overshadowed) and drug (saline and
SKF 81297). Expts 2a and 2b were run in a 2r3
factorial design with between subject factors of con-
ditioning group (NPE and PE) and drug (saline and
two doses of SCH23390). Finally, expt 3 was run in a
2r4 factorial design with between subject factors of
conditioning group (NPE and PE) and drug (saline,
SCH23390, Amph and Amph+SCH23390). The pre-
training data were subject to an additional repeated
measures factor of day. Statistical analysis was
performed using analysis of variance (ANOVA) with
a set at p<0.05 for the rejection of the null hypothesis.
Signiﬁcant interactions were analysed with simple
main eﬀects based on the pooled error term. Where
appropriate, LSD post-hoc tests were used to explore
diﬀerences between groups. Raw latency data (time to
ﬁrst lick at reshape) were log transformed so that their
distribution was suitable for parametric analysis.
Results
Expt 1a: eﬀect of 0.8 mg/kg SKF 81297 on
overshadowing and LI produced by 30 CS
pre-exposures
Pre-exposure
Analysis of the latencies to ﬁrst lick over the 5 d pre-
training revealed an eﬀect of day (F4,264=38.05,
p<0.001) as latencies to ﬁrst lick declined. This trend
was unaﬀected by to-be-conditioned or subsequent
drug group (max F8,264=1.15, p=0.33).
Reshape
Overall, the SKF 81297-treated animals took longer to
make the ﬁrst lick in the reshape session following
conditioning (F1,66=7.43, p<0.01) [mean log s (¡S.E.M.)
saline=0.91 (¡0.13) ; SKF 81297=1.36 (¡0.11)]. There
was also an eﬀect of group (F1,66=5.37, p<0.05) as the
overshadowed group had shorter latencies than both
the control (p<0.05) and PE group animals (p<0.05).
There was no interaction (F<1).
Test
There were no diﬀerences in the A period between any
of the experimental groups (max F2,66=1.18, p=0.31).
The mean suppression ratios to the light CS are dis-
played in Fig. 1. Inspection of this ﬁgure suggests
that, although the animals treated with SKF 81297
had overall lower suppression ratios (i.e. greater
conditioned suppression), they nonetheless showed
robust LI and overshadowing. This observation
was conﬁrmed by ANOVA, which yielded an eﬀect
of group (F2,66=21.92, p<0.001) and drug (F1,66=12.39,
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Fig. 1. The eﬀect of 0.8 mg/kg SKF 81297 (SKF) on latent
inhibition and overshadowing. Mean suppression ratios
to the light conditioned stimulus (¡S.E.M.) for control
(white bars), pre-exposed (PE; light grey bars) and
overshadowed (OS, dark grey bars) rats that had previously
been treated with either saline or 0.8 mg/kg SKF. * Indicates
signiﬁcant diﬀerence from similarly treated PE group
(p<0.05). # Indicates signiﬁcant diﬀerence from similarly
treated OS group (p<0.05).
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p<0.001) but no interaction. Thus, at a dose of
0.8 mg/kg SKF 81297 produced no selective eﬀects on
either LI or overshadowing.
Expt 1b: eﬀect of 0.4 mg/kg SKF 81297 on
overshadowing and LI produced by 30 CS
pre-exposures
Pre-training
Latencies to ﬁrst lick declined over the 5 d pre-training
(F4,264=19.57, p<0.001). The rate of decline did diﬀer
by the to-be-conditioned group (F4,264=3.47, p<0.05)
but by day 5 there were no diﬀerences between the
groups (all Fs<1).
Reshape
None of the experimental groups diﬀered in the
latency to ﬁrst lick in the reshape session following
conditioning (F2,66=1.66, p=0.19).
Test
Analysis of the A periods revealed an eﬀect of group
(F2,66=3.17, p<0.05) as the control group had higher A
periods than the PE group (p<0.05). This eﬀect inter-
acted with drug (F2,66=3.29, p<0.05) as the SKF 81297
controls took longer to make 50 licks compared to the
PE (p<0.05) and overshadowed (p<0.05) groups. As
the suppression ratio used to measure conditioning to
the light explicitly takes account of baseline diﬀer-
ences in responding, these eﬀects on the A period are
unlikely to account for the test results.
ANOVA revealed an eﬀect of conditioning group
(F2,66=31.4, p<0.001) but – as is clear from Fig. 2 – the
eﬀects of the conditioning treatment were not equiva-
lent across the two drug groups and there was a con-
ditioning group by drug interaction (F2,66=3.70,
p<0.05). The 0.4 mg/kg dose of SKF 81297 was with-
out eﬀect on conditioning in the control and over-
shadowing groups (max F1,66=1.2, p=0.28) but clearly
reduced LI as PE group animals treated with
SKF 81297 showed greater conditioning to the light
compared to their saline-injected counterparts (F1,66=
6.19, p<0.05). It should be noted, however, that
this eﬀect reﬂects an attenuation of LI rather than
an abolition as the pre-exposed SKF 81297-treated
animals nonetheless showed reduced suppression
relative to their non-pre-exposed controls (p<0.05).
Expt 2a: eﬀect of SCH23390 on LI produced by
10 light CS pre-exposures
Pre-training
The latency to ﬁrst lick declined over the 5 d pre-
training in all the experimental groups (F4,260=23.73,
p<0.001). This trend was unaﬀected by either drug or
conditioning group-to-be (max F8,260=1.61, p=0.123).
Reshape
Analysis of the latency to ﬁrst lick in the reshape
session revealed no eﬀect of conditioning group (F<1)
but an eﬀect of drug (F2,65=9.27, p<0.001) as both
doses of SCH23390 reduced the latency to ﬁrst
lick relative to saline-injected animals (min p<0.01).
There was no drugrconditioning group interaction
(F2,65=2.73, p=0.073).
Light test
There was no eﬀect of either drug nor of conditioning
group on the A period latencies (max F2,65=1.62,
p=0.21). The mean suppression ratios to the light CS
are presented in Fig. 3. ANOVA revealed a main eﬀect
of conditioning group (F2,65=8.15, p<0.01), but no
eﬀect of drug (F2,65=1.74, p=0.184) nor an interaction
(F<1), indicating that neither dose of SCH23390 had
any eﬀect on the level of LI produced with 10 pre-
exposures.
Expt 2b: eﬀect of SCH23390 on LI produced by 10
noise CS pre-exposures
Pre-training
There were no diﬀerences between any of the groups
in terms of the latency to ﬁrst lick or total amount
drunk in the pre-training session (all Fs<1).
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Fig. 2. The eﬀect of 0.4 mg/kg SKF 81297 (SKF) on latent
inhibition and overshadowing. Mean suppression ratios to
the light conditioned stimulus (¡S.E.M.) for control (white
bars), pre-exposed (PE, light grey bars) and overshadowed
(OS, dark grey bars) rats that had previously been treated
with either saline or 0.4 mg/kg SKF. * Indicates signiﬁcant
diﬀerence from similarly treated PE group (p<0.05).
# Indicates signiﬁcant diﬀerence from similarly treated
OS group (p<0.05).
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Reshape
There was a main eﬀect of drug (F2,66=5.66, p<0.05) as
both doses of SCH23390 reduced latencies to ﬁrst
lick in the reshape session (both p<0.05). There was,
however, no eﬀect of conditioning group and no in-
teraction (both Fs<1).
Noise test
None of the groups diﬀered in the time to make 50
licks in the absence of the noise CS (max F2,66=2.86,
p=0.64). Figure 4 displays the mean suppression
ratios to the noise CS. As is clear from this ﬁgure, both
doses of SCH23390 led to an overall reduction in
the conditioned suppression to the noise CS relative
to saline-injected animals. However, there was no
evidence of diﬀerential conditioning to the noise CS by
conditioning group. ANOVA revealed an eﬀect of
drug (F2,66=19.41, p<0.05) but no eﬀect of condition-
ing group or interaction (max F1,66=1.45, p=0.23).
Expt 3 : eﬀect of SCH23390 on amphetamine-induced
abolition of LI produced by 30 CS pre-exposures
Pre-training
Latencies to ﬁrst lick declined over the 5 d pre-training
(F4,352=33.89, p<0.001). This trend interacted with the
to-be-conditioned group but not drug (F4,352=3.68,
p<0.05). The PE group’s latencies overall declined
more slowly but by day 5 there were no diﬀerences
between the groups (all Fs<1).
Reshape
Analysis of the time to ﬁrst to lick revealed no eﬀect of
group (F1,88=1.93, p=0.17) but a signiﬁcant eﬀect of
drug (F3,88=16.38, p<0.001). This eﬀect arose because
the saline-treated animals took longer to make the
ﬁrst lick compared to the SCH23390 (p<0.001) and
Amph+SCH23390 (p<0.05) groups but less time
relative to animals treated with Amph alone (p<0.05).
These eﬀects of drug were not inﬂuenced by con-
ditioning group as there was no grouprdrug inter-
action (F<1).
Test
There was no eﬀect of either drug or conditioning
group on the time to make licks 2–50 in the absence of
the CS (F3,88=1.79, p=0.16).
As is clear from Fig. 5, the level of conditioning
seen to the CS diﬀered by drug and group. ANOVA
revealed no eﬀect of group (F1,88=3.19, p=0.078),
an eﬀect of drug (F3,88=12.82, p<0.001) and also a
grouprdrug interaction (F3,88=3.21, p<0.05). As ex-
pected, there was an eﬀect of pre-exposure in saline-
treated animals (F1,88=5.41, p<0.05) but this eﬀect was
abolished in animals-treated with Amph alone (F<1).
However, co-administration of SCH23390 in Amph-
treated animals blocked the Amph-induced abolition
of LI, in that statistically there was a signiﬁcant pre-
exposure eﬀect in these animals (F1,88=4.88, p<0.05).
Unexpectedly, in animals treated with SCH23390,
there was no evidence of diﬀerential conditioning by
group and (if anything) there was less conditioned
suppression in the NPE relative to the PE group, but
this trend failed to reach statistical signiﬁcance
(F1,88=2.24, p=0.138). This disruption of LI in animals
treated with SCH23390 appeared to be mediated
by drug action in the NPE condition as the level of
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Fig. 3. The eﬀect of 0.025 or 0.05 mg/kg SCH 23990 (SCH)
on latent inhibition [10 light conditioned stimulus (CS)
pre-exposures]. Mean suppression ratios to the light CS
(¡S.E.M.) for non-pre-exposed (control, white bars) and
pre-exposed (PE, light grey bars) rats that had previously
been treated with either saline or SCH.
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Fig. 4. The eﬀect of 0.025 or 0.05 mg/kg SCH 23990 (SCH)
on latent inhibition [10 noise conditioned stimulus (CS)
pre-exposures]. Mean suppression ratios to the noise CS
(¡S.E.M.) for non-pre-exposed (control, white bars) and
pre-exposed (PE, light grey bars) rats that had previously
been treated with either saline or SCH.
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conditioned suppression in the SCH23390 NPE group
was lower than all other NPE drug groups (p<0.05)
but the SCH23390 PE diﬀered only from the Amph PE
group (p<0.05).
Expt 4: assessment of locomotor activity
Data for 12 of the rats (six Amph and six Amph+
SCH23390) were lost due to computer failure so that
there were 18 animals in each of the drug groups.
Analysis of the total beam breaks revealed that ani-
mals that had previously been treated with Amph+
SCH23390 (at pre-exposure and conditioning) showed
lower levels of activity in response to the ampheta-
mine challenge relative to animals that had previously
been treated with amphetamine only (F1,34=15.1,
p<0.001) [total mean beam breaks (¡S.E.M.) : Amph
group=2297.8 (¡85.2) ; Amph+SCH23390 group=
1812.1(¡91.5)].
Discussion
Because of the dose-related reduction in LI (but not
overshadowing) after treatment with the D1 agonist
SKF 81297, the follow-up experiment with the D1
antagonist SCH23390 tested for increased selective
learning using the LI procedure (only) and with pro-
cedural variants standard to test for enhancement of
the LI eﬀect (weak pre-exposure). Accordingly, expt 2a
used 10 presentations of a 5 s light CS and expt 2b
used 10 presentations of a 5 s noise CS. Expt 3 reverted
to the standard number of pre-exposures (30) and the
same light CS as was used in expt 1 because these
parameters yield robust LI in normal animals that is
abolished by amphetamine (e.g. Nelson et al. 2011a).
The objective of expt 3 was to test for D1-mediated re-
versal of amphetamine eﬀects on LI. Thus, the current
experiments examined the role of D1 receptors in LI
and overshadowing. In expt 1, although LI was
somewhat reduced by SKF 81297, we found no evi-
dence that activation of D1 receptors was suﬃcient to
clearly abolish LI or overshadowing (O’Tuathaigh &
Moran, 2002, 2004). In expt 2, following up on the
attenuation of LI under 0.4 mg/kg SKF 81297, antag-
onism of D1 receptors failed to enhance LI. However,
expt 3 provided evidence for D1 receptor involvement
in the disruptive eﬀects of amphetamine on LI, in that
these were reversed by SCH23390. Expt 4 suggested
a mechanism in that the locomotor activity data are
consistent with the conjecture that treatment with
SCH23390 can prevent sensitized DA release.
Previously, the partial D1 agonist SKF 38393 has
been shown to have dissociable eﬀects on LI and
overshadowing: LI is spared but overshadowing can
be abolished by activation of D1 receptors (Feldon et al.
1991; Loskutova et al. 2010; O’Tuathaigh & Moran,
2002 ; Zelikowsky & Fanselow, 2010). Here we found
that at a dose of 0.8 mg/kg the full D1 agonist
SKF 81297 led to an overall increase in the level of
conditioning to the CS but this eﬀect was found in all
three conditioning groups irrespective of the animal’s
experience of the CS (i.e. whether novel, pre-exposed
or conditioned in compound). Thus, despite higher
levels of conditioning to the CS relative to saline-
injected animals, the SKF 81297 pre-exposed and
overshadowed animals nonetheless showed less con-
ditioned suppression to the CS relative to controls
treated with SKF 81297. At the lower dose of 0.4 mg/
kg, there was also some evidence that SKF 81297 atte-
nuated LI relative to saline-injected animals but there
was still diﬀerential conditioning to the CS between
pre-exposed and non-pre-exposed animals treated
with SKF 81297. Given that both LI and over-
shadowing manifest behaviourally as a reduction in
conditioning relative to control animals that have not
been pre-exposed to the CS or conditioned to the CS
in compound with a more intense CS, it is not the ab-
solute magnitude of conditioning to the CS that is the
critical determinant of the actions of a drug on LI and
overshadowing, but rather the level of conditioning
relative to control animals treated with that drug. On
this basis, SKF 81297 cannot be said to have abolished
either LI or overshadowing in the current experi-
ments.
With regard to LI, these results are consistent with
what has previously been found with the partial D1
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Fig. 5. The eﬀect of 0.02 mg/kg SCH 23390 (SCH) on the
disruptive eﬀects of 1 mg/kg amphetamine (Amph) on latent
inhibition. Mean suppression ratios to the light conditioned
stimulus (CS,¡S.E.M.) for non-pre-exposed (control, white
bars) and pre-exposed (PE, light grey bars) rats that had
previously been treated with saline, Amph, SCH or
Amph+SCH. * Indicates signiﬁcant diﬀerence from
similarly treated PE group (p<0.05).
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agonist SKF 38393 (Feldon et al. 1991; Loskutova et al.
2010) and provide yet further evidence that preferen-
tial stimulation of D1 receptors does not abolish LI.
It remains possible, however, that as both the direct
D2/3 agonist quinpirole as well as the direct D1/2
agonist apomorphine are equally without eﬀect on LI
(Feldon et al. 1991; Loskutova et al. 2010), the failure of
SKF 81297 to abolish LI may not be entirely attribu-
table to the DA receptor speciﬁcity of this agent but
rather to its being a direct agonist. It appears that LI
is only aﬀected by impulse-dependent DA release
whereas the DA release elicited by direct agonists is
not coupled to impulse ﬂow and, as such, LI is spared
following treatment with direct agonists (Gray et al.
1997; Weiner, 2003 ; Young et al. 2005).
There are reports from two independent labora-
tories of abolished overshadowing following treat-
ment with the partial D1 agonist SKF 38393
(O’Tuathaigh &Moran, 2002 ; Zelikowsky & Fanselow,
2010) ; a ﬁnding that we have failed to replicate here
with the full agonist SKF 81297. This apparent dis-
sociation in the eﬀects of SKF 81297 and SKF 38393
might be taken as evidence to suggest that over-
shadowing is diﬀerentially sensitive to partial and full
D1 agonists. However, in our hands, overshadowing
is similarly insensitive to treatment with low dose
amphetamine (Nelson et al. 2011a). Thus, it would
appear that dose and, in particular, strain of rat may
be a critical determinant of the sensitivity of over-
shadowing to pharmacological manipulations of fore-
brain DA systems.
Consistent with the failure of the D1 agonists to
abolish LI, treatment with the D1 antagonist SCH23390
did not facilitate LI under conditions of weak pre-
exposure, which do not yield LI in controls. Moreover,
in expt 3, which used standard LI parameters suitable
for testing for amphetamine-induced abolition (30 CS
pre-exposures), there was no evidence of a pre-
exposure eﬀect in animals treated with SCH23390.
One possible explanation for the inability of
SCH23390 to enhance LI is that, as well as being
a potent D1 antagonist, it also acts as an agonist at
5-HT2c receptors (e.g. Briggs et al. 1991; Millan et al.
2001). Although this additional action cannot com-
pletely be ruled out as a potential explanation of the
failure of SCH23390 to enhance LI, increased 5-HT
neurotransmission has been shown to facilitate LI. For
example, treatment with the 5-HT reuptake inhibitor
sertraline has been found to potentiate LI (Loskutova
et al. 1990).
Alternatively, it could be argued that the failure to
demonstrate LI enhancement in animals treated with
SCH23390 stems from a general learning impairment,
in that animals in both in pre-exposed and non-
pre-exposed conditions exhibited relatively high sup-
pression ratios (i.e. poor learning). Thus, a ﬂoor eﬀect
could potentially explain the lack of a drug eﬀect
and mask diﬀerences between the two pre-exposure
groups. However, there was no statistical evidence
that non-pre-exposed animals diﬀered by drug and,
subsequently, in expt 2b it was shown that – even with
more robust levels of conditioning – SCH23390 did
not enhance LI. Furthermore, the current ﬁnding re-
plicates previous reports that the selective D1 antago-
nists NNC 01-0112 and SCH 39166 similarly do not
potentiate LI with weak CS pre-exposure (Trimble
et al. 2002). Taken together, these results provide
compelling evidence that blockade of D1 receptors
does not facilitate LI. This proposition is entirely con-
sistent with the well-established ﬁnding that anti-
psychotics facilitate LI, an eﬀect that is widely
attributed to the high aﬃnity of such drugs for D2
receptors (e.g. Feldon & Weiner, 1991 ; Shadach et al.
2000; Weiner, 2003 ; Weiner & Feldon, 1987).
However, as abolished and enhanced LI may
depend on dissociable neural substrates (e.g. Gal et al.
2005; Nelson et al. 2010; Weiner & Arad, 2009), the
demonstration that D1 antagonists do not enhance
LI does not preclude their involvement in LI (Bay-
Richter et al. 2009; O’Callaghan et al. 2010). Thus, in
expt 3, we tested the ability of SCH23390 to reverse
amphetamine-induced disruption of LI using exper-
imental parameters explicitly designed to test for LI
abolition (30 pre-exposures). We found that, although
on its own SCH23390 did not enhance LI, it blocked
amphetamine-induced disruption of LI such that ani-
mals treated with both amphetamine and SCH23390
exhibited LI. Previously, both typical and atypical
antipsychotics have been shown to reverse the dis-
ruptive eﬀects of amphetamine on LI (e.g. Gosselin
et al. 1996; Moran et al. 1996; Warburton et al. 1994;
Weiner et al. 1996) indicating amphetamine eﬀects on
LI are mediated in part by its actions at D2 receptors.
The current ﬁndings suggest that amphetamine also
exerts its disruptive eﬀects on LI via actions at D1 re-
ceptors and concurrent antagonism of D1 receptors is
suﬃcient to reverse amphetamine-induced disruption
of LI. This ﬁnding is entirely consistent with other
evidence demonstrating that the behavioural eﬀects of
amphetamine can depend on co-activation of both D1
and D2 receptors in a variety of behavioural paradigms
(e.g. Ranaldi & Beninger, 1993 ; St Onge & Floresco,
2009). Moreover, the disruptive eﬀects of nicotine on
LI, which are thought to be modulated by activation
of the mesolimbic DA system (Joseph et al. 1993),
are similarly blocked by concurrent administration of
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SCH23390 (Young et al. 2005). Recently, it has been
shown that, when tested with standard LI exper-
imental parameters (i.e. low number of conditioning
trials, high number of pre-exposures) haloperidol
paradoxically attenuates LI but this eﬀect is blocked by
concurrent treatment with the D1 agonist SKF 38393
(Loskutova et al. 2010). These data point to the im-
portance of interactions between D1 and D2 receptors
in regulating the behavioural processes underlying LI.
Interestingly, antagonism of D1 receptors blocks the
development of sensitization to the locomotor acti-
vating eﬀects of amphetamine (Vezina, 1996 ; Vezina &
Stewart, 1989). Here we also found that animals pre-
viously treated with SCH23390 and amphetamine
showed less locomotor activity in response to a sub-
sequent amphetamine challenge relative to animals
that had been treated with amphetamine alone. As
sensitized DA release by amphetamine is required to
abolish LI (Joseph et al. 2000), one possible mechanism
by which SCH23390 may reverse amphetamine eﬀects
on LI is by preventing sensitized DA release.
A further and somewhat unexpected ﬁnding in expt
3 was the demonstration that SCH23390 administered
alone appeared to disrupt LI, in that there was no
diﬀerence in the level of conditioning to the CS
between the PE- and NPE-group animals. It should
be noted that this paradoxical disruption of LI by
SCH23390 is qualitatively diﬀerent from the abolition
produced by amphetamine. Amphetamine-induced
disruption of LI manifests as a selective increase in
conditioning to the CS in the PE group (i.e. reduced
LI), whereas the apparent disruption seen after
SCH23390 is mediated by a decrease in conditioning
to the CS in non-pre-exposed animals. To exclude non-
speciﬁc drug eﬀects on learning per se, drug-induced
disruption of LI is only reliably demonstrated when
drug actions occur in the pre-exposed condition (as is
the case with amphetamine ; for a full discussion of
these issues, see Weiner & Arad, 2009). As the lack of
diﬀerence in between the NPE and PE animals cannot
be attributed to an action of the drug on conditioning
in the PE group but rather to reduced conditioning
in the NPE group, the eﬀect of SCH23390 more likely
reﬂects a non-speciﬁc eﬀect of SCH23390 on con-
ditioning. Conversely, in expt 1, the D1 agonist
SKF 81297 generally increased conditioning (at 0.8
but not at 0.4 mg/kg). This proposition is broadly
consistent with other evidence suggesting that D1
receptor antagonists can disrupt Pavlovian con-
ditioning (e.g. Eyny & Horvitz, 2003). In the present
study, such an eﬀect is controlled for by the compari-
son of PE and NPE groups; despite its eﬀect on the
baseline level of fear conditioning, treatment with
SCH23390 nonetheless restored LI in amphetamine-
treated rats.
Conclusions
These experiments provide novel insights into DA
mechanisms in LI. The ﬁnding that neither stimulation
nor blockade of D1 receptors had any unambiguous
eﬀect on LI suggests that in isolation D1 receptors
do not play a role in the modulation of LI by DA.
Nonetheless, the demonstration that antagonism of D1
receptors restored normal LI in amphetamine-treated
rats indicates that activity at D1 receptors, perhaps
through interactive eﬀects with D2 receptors, con-
tributes to the dopaminergic modulation of the behav-
ioural processes underlying LI (Loskutova et al.
2010).
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